Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β- d -Glucan Synthase: Implication for the Existing Susceptibility Breakpoint
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Thirteen Candida glabrata strains harboring a range of mutations in hot spot regions of FKS1 and FKS2 were studied. The mutations were linked to an echinocandin reduced susceptibility phenotype. Sequence alignments showed that 11 out of the 13 mutants harbored a mutation in FKS1 or FKS2 not previously implicated in echinocandin reduced susceptibility in C. glabrata . A detailed kinetic characterization demonstrated that amino acid substitutions in Fks1p and Fks2p reduced drug sensitivity in mutant 1,3-β- d -glucan synthase by 2 to 3 log orders relative to that in wild-type enzyme. These mutations were also found to reduce the catalytic efficiency of the enzyme ( V max ) and to influence the relative expression of FKS genes. In view of the association of FKS mutations and reduced susceptibility of 1,3-β- d -glucan synthase, an evaluation of the new CLSI echinocandin susceptibility breakpoint was conducted. Only 3 of 13 resistant fks mutants (23%) were considered anidulafungin or micafungin nonsusceptible (MIC > 2 μg/ml) by this criterion. In contrast, most fks mutants (92%) exceeded a MIC of >2 μg/ml with caspofungin. However, when MIC determinations were performed in the presence of 50% serum, all C. glabrata fks mutants showed MICs of ≥2 μg/ml for the three echinocandin drugs. As has been observed with Candida albicans , the kinetic inhibition parameter 50% inhibitory concentration may be a better predictor of FKS -mediated resistance. Finally, the close association between FKS1/FKS2 hot spot mutations provides a basis for understanding echinocandin resistance in C. glabrata .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“C. glabrata may upregulate FKS2 expression to compensate for its decreased catalytic capacity [36]”
From Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata (2012) · cites this paper as [36]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As with azoles, resistance to echinocandin therapy frequently involves mutations in genes encoding the drug target, FKS1 (Candida, Cryptococcus, and Aspergillus spp.) and FKS2 (C. glabrata only)33,34.”
From Molecular mechanisms governing antifungal drug resistance (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“intrinsic genetic, structural, and binding variations in Fks enzymes across Candida species create distinct baseline susceptibilities and predispose certain species to develop heteroresistance under selective pressure from specific echinocandins [51].”
From Calcineurin‐Dependent Stress Adaptation Enables Caspofungin Heteroresistance Leading to Stable Resistance in Candida Glabrata (2026) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, FKS1 point mutations are commonly detected in ECN-resistant (ECN-R) Candida spp. (24, 25).”
From Transcriptomics and Phenotyping Define Genetic Signatures Associated with Echinocandin Resistance in Candida auris (2022) · cites this paper as [24]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Point mutations in one of two specific hot-spot regions of FKS genes increase the half maximal inhibition concentration (IC50) of an echinocandin in vitro by up to 3 orders of magnitude67.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [67]
Experimental — accuracy not yet measured
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics
White, T. J., Bruns, T., Lee, S., & Taylor, J. (1990) · PCR Protocols · doi:10.1016/b978-0-12-372180-8.50042-1 · Cited by 36,648
Self-citationA new mathematical model for relative quantification in real-time RT-PCR
Pfaffl, M. W. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.9.e45 · Cited by 34,610 · cited 1×
“relative expression levels were evaluated using the Pfaffl method (23).”
MethodPCR protocols — A guide to methods and applications
(1990) · Trends in Genetics · doi:10.1016/0168-9525(90)90186-a · Cited by 11,781
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“glabrata infections are a concern due to their high mortality rates (38) and the tendency of this microorganism to rapidly develop resistance to azole antifungal agents (6, 11, 15, 25, 31, 34).”
BackgroundDenning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131 · cited 1×
“The introduction of the antifungal drug caspofungin (CSF) in 2001 was a significant advance in the treatment of these infections since these lipopeptides’ mode of action is independent of existing antifungal drugs (7, 16, 36).”
BackgroundReference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard
Rex, J. H., & Clinical (2008) · Clinical and Laboratory Standards Institute eBooks · Cited by 1,052
Fidel, P. L., Vazquez, J. A., & Sobel, J. D. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.80 · Cited by 953 · cited 1×
“glabrata infections are a concern due to their high mortality rates (38) and the tendency of this microorganism to rapidly develop resistance to azole antifungal agents (6, 11, 15, 25, 31, 34).”
BackgroundTrick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Resistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512 · cited 3×
“These IC50s were comparable with previous data obtained for other echinocandin-resistant Candida species strains with FKS mutations (13, 14, 21, 22).”
BackgroundResultSelf-citationPark, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Self-citation
Cited by
Items 301–335 of 335
NASİBOĞLU, B., Dokuzeylül, B., Alkan, F. A., Barutçu, Ü. B., & Or, M. E. (2018) · Journal of Advances in VetBio Science and Techniques · doi:10.31797/vetbio.482028
Espinel‐Ingroff, A., Sanguinetti, M., & Posteraro, B. (2019) · Current Fungal Infection Reports · doi:10.1007/s12281-019-0336-2
Antifungal Consideration for Transplant Recipients
Dubrovskaya, Y., Merl, M. Y., Perlin, D. S., & Safdar, A. (2019) · Springer eBooks · doi:10.1007/978-1-4939-9034-4_52
Self-citationCelis, D. A. L., Aponte, J. A. M., & Castillo, J. M. M. (2019) · Cited by 1
(2010) · Yeast · doi:10.1002/yea.1715
Use of Novel Tools to Probe Drug Resistance in Fungi
Zhao, Y., & Perlin, D. S. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0667-3_21-1
Self-citationLockhart, S. R., & Warnock, D. W. (2015) · ASM Press eBooks · doi:10.1128/9781555817381.ch129 · Cited by 1
Perlin, D. S. (2017) · Springer eBooks · doi:10.1007/978-3-319-46718-4_29
Self-citationLepak, A. J., & Andes, D. R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819990-9.00018-4 · Cited by 2
Warnock, D. W. (2011) · Wiley eBooks · doi:10.1128/9781555816728.ch126 · Cited by 1
Li, Y., Hou, X., Li, R., Liao, K., Ma, L., Wang, X., Ji, P., Kong, H., Xia, Y., Ding, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24580400
Candida albicans - Epidemiology and Treatment
Behzadi, P. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1001505
MDR in Candida: The Real Storm
Srivastava, P., Tiwari, S., Kumar, M., Murhekar, M. V., & Dwivedi, G. R. (2024) · Springer eBooks · doi:10.1007/978-981-97-4909-6_4
Bohner, F. (2024) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.12031
Rezafungin: A β-(1,3)-D-glucan synthase inhibitor as antifungal drug derived from Echinocandin B0
Luo, H., Zang, Y., & Zhang, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33885-4.00014-7 · Cited by 1
Gupta, D., Andole, S., & Mishra, K. (2025) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-025-00724-y
Bilbao Bilbao, N. (2018) · Communities in ADDI (Universidad del Pais Vasco)
Cob-Delgado, M., Ruiz-Mayorga, A., Ramírez-Cardoce, M., Cordero-Laurent, E., & Gutiérrez, R. (2026) · Medical Mycology · doi:10.1093/mmy/myag004
Antifungal Activity of Lipophilic Bisphosphonates
Pandey, A. M., Zhou, R., Singh, D., Li, F., He, M., Le, A. M., Herdrich, J., Chen, Y., Shah, R., Adusei-Poku, S., et al. (2026) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c00838
Functional Genomic Analysis of Protein Kinases in the Human Fungal Pathogen Candida albicans
Lee, Y. (2023) · TSpace (University of Toronto)
Yu, L., Yi, W., Zheng, W., Zheng, D., Li, J., Luo, L., Luo, G., Xia, M., You, L., & Yong, J. (2026) · Current Microbiology · doi:10.1007/s00284-026-04805-5
L'interaction Hsp90/co-chaperonnes : nouvelle cible pour le traitement des candidoses invasives
Rouges, C. (2023) · theses.fr (ABES) · doi:10.70675/40b24a3fz159ez4d8ez8a34zdd8ffa1c22fa
Functional and structural studies of drug efflux by Cdr1p, an ABC transporter of Candida fungi
Pata, J. (2023) · theses.fr (ABES) · doi:10.70675/6adbc74dzad88z4878zbfc2z4a16da9e0458
From culture to metagenomics: A paradigm shift in diagnosing infective endocarditis
ElHefnawi, M., Amin, D. H., Elfiky, A. M., Tamam, F. M. M., Elabiad, M. A., Zada, S. K., & Abu-Shahba, N. (2026) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2026.117449
Emerging Antifungal Resistance in Ocular Infections
de Oliveira, H. C., Tabuse, A. M., Höfling-Lima, A. L., & Rodrigues, A. M. (2026) · Springer eBooks · doi:10.1007/978-3-032-19923-2_3
Micafungin exposure drives multidrug resistance in Clavispora lusitaniaePreprint
Wash, E., Scott, N. E., Metzner, K., Zhou, X., Dasilva, D., de Sá, N. P., Usmani, S. A., Sa, N. F. V. D., Poeta, M. D., & Selmecki, A. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.29.735437
“Mutations that alter the binding of drug targets, like Fks1 and Erg11, are common in resistant isolates (30–33).”
Antifungal resistance: from classical mechanisms to the expanding role of acetyltransferases
Werneck, S. M. C., Gouveia‐Eufrásio, L., de Freitas, G. J. C., de Carvalho, D. S., César, I. C., Rossato, L. L., Bastos, R. W., Peres, N. T. A., & Santos, D. A. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-026-01273-8
“Concerning echinocandin resistance, mutations in the FKS1 gene, encoding a catalytic subunit of the 1,3-β-glucan synthase complex, have been identified in C. albicans , Cryptococcus spp., and Aspergillus spp., whereas mutations in FKS2 contribute specifically to resistance in C. glabrata [88, 89].”
Sung, M., Chang, S., Leem, A. Y., Lee, C. H., Chung, K. S., Kim, Y. S., Kim, J. M., & Lee, S. H. (2026) · Journal of Fungi · doi:10.3390/jof12070495
“Genuine echinocandin resistance is mediated by FKS1/FKS2 hot-spot mutations and confers cross-resistance across the entire class, so the preserved micafungin and anidulafungin susceptibility argues against FKS-mediated resistance in these isolates [31,32].”
Self-citationSaha, P., Debbarma, K., Rathinam, A., Das, S., & Chellam, P. V. (2026) · Journal of the Indian Chemical Society · doi:10.1016/j.jics.2026.102877
Parallel evolution under constraint shapes echinocandin resistance in Candida aurisPreprint
Cauldron, N. C., Dort, E. N., Weeks, G., Rogers, P. D., & Cuomo, C. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.30.748140
Structural basis of caspofungin inhibition of Nakaseomyces glabratus Fks1Preprint
Rasel, M. S. I., Raghav, D., Suchana, F. J., de Carvalho, R. S. A., & Tomasiak, T. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.21.760291
“Mutants tend to cluster onto the membrane-facing surface of the transmembrane region and are classified into “hotspot” regions called hotspot-1 (625-633), hotspot-2 (1340-1344), and hotspot-3 (676-686), which are highly conserved regions 32,34 .”
Maroc, L., Gervais, N. C., Fogal, M., Bates, E., Westmacott, G., McQueen, P., McCorrister, S., Grant, C., Johnson, S., & Shapiro, R. S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.11.03.763960
Metadata
- Authors
- Garcia-Effron, G., Lee, S., Park, S., Cleary, J. D., & Perlin, D. S.
- Affiliations
- Public Health Research Institute, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, New Jersey 07103
- University of New Mexico (US)
- Rutgers New Jersey Medical School (US)
- University of Mississippi (US)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2009-09
- Volume
- 53
- Issue
- 9
- Pages
- 3690-3699
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2737881
- OpenAlex
- W2163061527
- Cited by
- 323
- References
- 40
- Citations by year
- 2026: 18 · 2025: 12 · 2024: 12 · 2023: 14 · 2022: 10 · 2021: 17 · 2020: 22 · 2019: 18 · 2018: 20 · 2017: 26 · 2016: 14 · 2015: 17 · 2014: 25 · 2013: 16 · 2012: 26
- FWCI
- 18.86
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (AI069397, R01AI069397)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida glabrata, echinocandin resistance, 1,3-β-D-glucan synthase, FKS1, FKS2, hot spot mutations, anidulafungin, micafungin, caspofungin, susceptibility breakpoints, enzyme kinetics, catalytic efficiency, antifungal resistance
- MeSH terms
- Antifungal Agents, Fungal Proteins, Glucosyltransferases, Reverse Transcriptase Polymerase Chain Reaction, Drug Resistance, Fungal, Candida glabrata, Echinocandins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.